GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Change In Payables And Accrued Expense

NOTV (Inotiv) Change In Payables And Accrued Expense : $1.9 Mil (TTM As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Change In Payables And Accrued Expense?

Inotiv's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2024 was $-4.8 Mil. It means Inotiv's Accounts Payable & Accrued Expense declined by $4.8 Mil from Mar. 2024 to Jun. 2024 .

Inotiv's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2023 was $-2.4 Mil. It means Inotiv's Accounts Payable & Accrued Expense declined by $2.4 Mil from Sep. 2022 to Sep. 2023 .

Inotiv Change In Payables And Accrued Expense Historical Data

The historical data trend for Inotiv's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Change In Payables And Accrued Expense Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 -1.99 7.72 6.62 -2.38

Inotiv Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.46 4.54 -5.34 7.50 -4.83

Inotiv Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Inotiv's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
PRPH XGN OCX PRE ENZ STIM BNR BIOQ VNRX BIAF TMO DHR XSWX:LONN IQV A IDXX MTD ILMN SHSE:603259 WAT
Traded in Other Exchanges
N/A
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Website
https://www.inotivco.com
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065